Medical
-
SpliSense announced that it has initiated the Phase 2b portion of the SPL84-02 trial of the SPL84 inhaled antisense oligonucleotide in CF patients with the 3849+10kb C→T splicing mutation in the CFTR gene. The Phase… Read more . . .
-
California-based SMSbiotech announced that the FDA has cleared its IND for a Phase 1b trial of its inhaled small mobile stem (SMS) cell therapy in patients with COPD and that the company intends to initiate… Read more . . .
-
Agomab Therapeutics has announced that the final part of a Phase 1 study of its AGMB-447 inhaled ALK5 inhibitor, which enrolled patients with idiopathic pulmonary fibrosis, demonstrated “a generally favorable safety and tolerability profile” in… Read more . . .
-
Pulmovant has announced that the Phase 2 PHocus clinical trial of its inhaled dry powder mosliciguat in patients with pulmonary hypertension due to interstitial lung disease (PH-ILD) met its primary endpoint, demonstrating a significant reduction in… Read more . . .
-
Leyden Laboratories has announced that it acquired intranasal RNA therapy developer RIGImmune sometime earlier this year. The company also reported results from a Phase 1 study of RIGImmune’s RIG-101, an intranasal innate immune modulator for… Read more . . .
-
MannKind and Rose Pharma have announced a collaboration agreement that gives Rose a worldwide license for development of its ROSE-010 rapid-acting GLP-1 as an inhaled therapy for weight loss using MannKind’s Technosphere dry powder technology.… Read more . . .
-
AirNexis Therapeutics has announced that a Chinese Phase 2b study of AN01 (HSK39004) PDE3/4 inhibitor DPI in COPD patients that was conducted by Haisco Pharmaceutical met its primary endpoint. AirNexis launched in early 2026 with… Read more . . .
-
Chinese biotech Rezubio has announced the initiation of a Phase 1 PK/PD study of RZ-520, which Rezubio describes as “a novel inhaled therapeutic drug candidate for the treatment of chronic respiratory diseases.” According to Rezubio,… Read more . . .
-
According to Liquidia, the FDA has granted Fast Track designation to the company’s Yutrepia inhaled dry powder treprostinil for the treatment of Raynaud’s phenomenon associated with systemic sclerosis (SSc-RP.). Yutrepia is currently approved in the… Read more . . .
-
Milestone Pharmaceuticals has announced the initiation of the Phase 3 ReVeRA-301 study of etripamil nasal spray in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). The trial is expected to enroll about 150 patients who… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland